Rationale: To formally determine the repeatability of Ga-68 PSMA lesion uptake in both relapsing and metastatic tumor. In addition, it was hypothesized that the BPL algorithm Q. Clear has the ability to lower SUV signal variability in the small lesions typically encountered in Ga-68 PSMA PET imaging of prostate cancer.

Methods: Patients with biochemical recurrence of prostate cancer were prospectively enrolled in this single center pilot test-retest study and underwent two Ga-68 PSMA PET/CT scans within 7.9 days on average. Lesions were classified as suspected local recurrence, lymph node metastases or bone metastases. Two datasets were generated: one standard PSF + OSEM and one with PSF + BPL reconstruction algorithm. For tumor lesions, SUVmax was determined. Repeatability was formally assessed using Bland-Altman analysis for both BPL and standard reconstruction.

Results: A total number of 65 PSMA-positive tumor lesions were found in 23 patients (range 1 to 12 lesions a patient). Overall repeatability in the 65 lesions was -1.5% ± 22.7% (SD) on standard reconstructions and -2.1% ± 29.1% (SD) on BPL reconstructions. Ga-68 PSMA SUVmax had upper and lower limits of agreement of +42.9% and -45.9% for standard reconstructions and +55.0% and -59.1% for BPL reconstructions, respectively (NS). Tumor SUVmax repeatability was dependent on lesion area, with smaller lesions exhibiting poorer repeatability on both standard and BPL reconstructions (F-test, < 0.0001).

Conclusion: A minimum response of 50% seems appropriate in this clinical situation. This is more than the recommended 30% for other radiotracers and clinical situations (PERCIST response criteria). BPL does not seem to lower signal variability in these cases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233885PMC
http://dx.doi.org/10.3390/diagnostics11061100DOI Listing

Publication Analysis

Top Keywords

ga-68 psma
20
bpl reconstructions
12
psma pet/ct
8
prostate cancer
8
lesions
8
signal variability
8
tumor lesions
8
standard reconstructions
8
bpl
7
repeatability
6

Similar Publications

 This article evaluates whether parameters derived from the gallium-68-labeled prostate-specific membrane antigen ( Ga-PSMA) positron emission tomography/computed tomography (PET/CT) imaging studies of primary prostate cancer (PCa) lesions were associated with Gleason score (GS), D'Amico risk class, Candiolo nomograms, and the metastatic status of the disease.  We retrospectively evaluated newly diagnosed PCa patients who underwent Ga-PSMA PET/CT before therapy. Age, baseline serum prostate-specific antigen (PSA), and metastatic status were recorded.

View Article and Find Full Text PDF

Synthesis and Preclinical Evaluation of a Bispecific PSMA-617/RM2 Heterodimer Targeting Prostate Cancer.

ACS Med Chem Lett

November 2024

Radiochemical Studies Laboratory, INRASTES, N.C.S.R. "Demokritos", Agia Paraskevi Attikis, 15310 Athens, Greece.

Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) have been used for diagnostic molecular imaging/therapy of prostate cancer (PCa). To address tumor heterogeneity, we synthesized and evaluated a bispecific PSMA/GRPR ligand () combining PSMA-617 () and the GRPR antagonist RM2 () with the radiometal chelator DOTA. was radiolabeled with Ga ([Ga]Ga-) and Lu ([Lu]Lu-).

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the feasibility and short-term outcomes of a new treatment for prostate cancer recurrence called PSMA radioguided salvage pelvic lymph node dissection (S-PLND), which helps detect and remove cancerous lymph nodes using advanced imaging techniques.
  • In a group of 14 patients, results showed that the majority (93%) had successful detection and removal of cancerous targets, and there were no complications from the procedure, indicating its safety.
  • Although some patients experienced a decline in prostate-specific antigen (PSA) levels after surgery, further research is needed to refine patient selection and understand the long-term clinical benefits of this treatment.
View Article and Find Full Text PDF

The radiometal gallium-68 (Ga-68) has garnered significant interest due to its convenient production via compact and widely available generators and the high performance of Ga-labeled compounds for positron-emission tomography (PET) imaging for cancer diagnosis and management of patients undergoing targeted radionuclide therapy. Given the short half life of Ga-68 (68 min), microfluidic-based radiosynthesis is a promising avenue to establish very rapid, efficient, and routine radiolabeling with Ga-68; however, the typical elution volume of Ga-68 from a generator (4-10 mL) is incompatible with the microliter reaction volumes of microfluidic devices. To bridge this gap, we developed a microscale cartridge-based approach to concentrate Ga-68.

View Article and Find Full Text PDF
Article Synopsis
  • Brain metastatic carcinoma from prostate cancer is uncommon, but identification through imaging like [Ga]PSMA PET/CT can be complicated by other brain tumors that also show uptake.
  • A 70-year-old male with high-risk prostate cancer had a solitary brain lesion confirmed as metastatic adenocarcinoma after surgical resection, followed by targeted Gamma Knife radiosurgery and androgen deprivation therapy.
  • The case highlights the importance of confirming the diagnosis histologically and shows that with appropriate treatment, significant control of the cancer can be achieved, even in rare brain metastases.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!